Metronidazole in Crohn's disease. A double blind cross-over clinical trial

Scand J Gastroenterol. 1978;13(1):123-7. doi: 10.3109/00365527809179816.

Abstract

Twenty-two patients with active Crohn's disease treated with salazosulfapyridin or prednisone, were in addition given metronidazole 1.000 mg daily or placebo for two months each in a double-blind cross-over study. No statistically significant effect was observed on the overall clinical condition in the 20 patients who completed the trial, although haemoglobin rose and ESR fell significantly in the metronidazole periods. In the 6 patients with colonic involvement only an improvement was registered both in symptoms and laboratory values.

Publication types

  • Clinical Trial
  • Controlled Clinical Trial
  • Randomized Controlled Trial

MeSH terms

  • Blood Sedimentation
  • Clinical Trials as Topic
  • Crohn Disease / blood
  • Crohn Disease / drug therapy*
  • Double-Blind Method
  • Drug Evaluation
  • Hemoglobins / analysis
  • Humans
  • Metronidazole / therapeutic use*

Substances

  • Hemoglobins
  • Metronidazole